ERBB2 and breast cancer: Further, although only amplified MYC did not significantly worsen the prognosis in breast cancer patients categorized as ER‐positive, HER2‐negative, and high‐proliferative subtype, patients with both high‐expressed CLK2 and MYC amplification showed significantly poor outcomes (Fig 7C).